公开(公告)号：US09533043B2

公开(公告)日：2017-01-03

申请号：US14036969

申请日：2013-09-25

Applicant: BioNTech AG

Inventor： Özlem Türeci ,  Ugur Sahin ,  Sandra Schneider ,  Gerd Helftenbein ,  Volker Schlüter ,  Dirk Usener ,  Philippe Thiel ,  Michael Koslowski

IPC: A61K39/395 ,  A61K51/10 ,  A61K47/42 ,  C07K16/30 ,  C12Q1/68 ,  C07K14/47 ,  A61K45/06 ,  C07K16/28 ,  A61P35/00 ,  G01N33/53

CPC classification number: A61K39/39558 ,  A61K39/395 ,  A61K45/06 ,  C07K14/4748 ,  C07K16/28 ,  C07K16/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/53

Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.

Abstract translation: 本发明的分离的截短的脱骨髓蛋白4（DSG4）多肽剪接变体的特征在于缺乏在具有SEQ ID NO：75的多核苷酸序列的DSG4基因的外显子9或超出外显子10之前编码的区域的氨基酸序列。还公开了 是在患者中诊断癌症或监测其过程的方法。 该方法包括在患者的组织样品中检测包含由具有SEQ ID NO：75的多核苷酸序列的DSG4基因或截短的DSG4多肽剪接变体编码的DSG4多肽的细胞外结构域的肿瘤相关抗原的表达 其特征在于缺乏在DSG4基因的外显子9或超出外显子10之前编码的区域的氨基酸序列。

公开(公告)号：US20160201137A1

公开(公告)日：2016-07-14

申请号：US14912813

申请日：2014-08-19

Applicant: BIONTECH AG ,  STRATIFYER MOLECULAR PATHOLOGY GMBH

Inventor： Ralph Wirtz ,  Christoph Kneip

IPC: C12Q1/68

Abstract: The present invention relates to an in vitro method of identifying a molecular subtype of a tumor in a cancer patient and to a method of stratifying a cancer patient for tumor treatment. The present invention further relates to kits that are useful for identifying a molecular subtype of a tumor in a cancer patient.

Abstract translation: 本发明涉及鉴定癌症患者肿瘤的分子亚型的体外方法和癌症患者分层肿瘤治疗的方法。 本发明还涉及可用于鉴定癌症患者中肿瘤的分子亚型的试剂盒。

公开(公告)号：US20160195539A1

公开(公告)日：2016-07-07

申请号：US15046700

申请日：2016-02-18

Applicant: BioNTech AG

Inventor： Özlem TÜRECI ,  Ugur SAHIN ,  Gerd HELFTENBEIN ,  Volker SCHLÜTER

IPC: G01N33/574

CPC classification number: G01N33/57492 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/30 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N2800/56

Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.

公开(公告)号：US20160125129A1

公开(公告)日：2016-05-05

申请号：US14787110

申请日：2014-05-07

Applicant: BIONTECH AG ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄ- TSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAIN

Inventor： Ugur Sahin ,  Arbel David Tadmor ,  John Christopher Castle ,  Sebastian Boegel ,  Martin Löwer

IPC: G06F19/18 ,  A61K39/00 ,  C12Q1/68

CPC classification number: G16B20/00 ,  A61K39/0011 ,  C12Q1/6886 ,  C12Q2600/156

Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.

Abstract translation: 本发明涉及预测T细胞表位的方法。 特别地，本发明涉及用于预测肽或多肽如肿瘤相关新抗原的修饰是否是免疫原性的方法。 本发明的方法特别适用于提供特异于患者肿瘤的疫苗，因此在个体化的癌症疫苗的背景下。

公开(公告)号：US09061007B2

公开(公告)日：2015-06-23

申请号：US13826030

申请日：2013-03-14

Applicant: BioNTech AG ,  Johannes Gutenberg-Universität Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski

IPC: A61K31/21 ,  A61K39/395 ,  C12Q1/68 ,  G01N33/574 ,  A61K31/7088 ,  C12N15/82 ,  A61K47/48

CPC classification number: C12Q1/6886 ,  A61K31/7088 ,  A61K39/39558 ,  A61K47/6807 ,  C07K16/28 ,  C07K16/2866 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1138 ,  C12N15/8218 ,  C12N2310/11 ,  C12N2310/14 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/57484 ,  G01N33/57492 ,  G01N2333/715 ,  G01N2333/7158 ,  G01N2333/916

Abstract: The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behavior of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions.

Abstract translation: 本发明涉及有可能评估和/或预测癌症疾病，癌症疾病的转移行为和/或癌症复发的方法。 特别地，本发明的方法使得有可能评估和/或预测癌症转移的发生，特别是远处转移。 优选地，本发明的方法允许区分恶性与良性状况。

公开(公告)号：US20150152186A1

公开(公告)日：2015-06-04

申请号：US14553669

申请日：2014-11-25

Applicant: BioNTech AG

Inventor： Klaus Pfizenmaier ,  Harald Wajant ,  Dieter Moosmayer ,  Thomas Wuest

IPC: C07K16/28 ,  C07K14/705 ,  C07K14/525

CPC classification number: C07K16/2866 ,  A61K47/6899 ,  B82Y5/00 ,  C07K14/525 ,  C07K14/70575 ,  C07K2319/00

Abstract: Subject matter of the invention are antibody-cytokine fusion proteins having proapoptotic and immune modulating properties, but wherein the cytokine moiety a priori has a bioactivity which is very low or restricted to certain receptor subtypes. These reagent exert their full biological activity via the corresponding cytokine receptor(s) only after antibody-mediated binding of the fusion protein to a specific cell membrane-expressed target molecule. By suitable choice of the antibody specificity, the cytokine activity is directed to the tissue, e.g. tumour tissue, to be treated, and a therapeutic agent can be produced being specifically designed/optimised for the respective indication/tumour entity.

Abstract translation: 本发明的主题是具有促细胞凋亡和免疫调节性质的抗体 - 细胞因子融合蛋白，但是其中先前的细胞因子部分具有非常低的或限于某些受体亚型的生物活性。 这些试剂只有在融合蛋白与特异性细胞膜表达的靶分子的抗体介导的结合之后才通过相应的细胞因子受体发挥其完整的生物活性。 通过适当选择抗体特异性，将细胞因子活性导向组织，例如， 可以对各种适应症/肿瘤实体进行特异性设计/优化来制备待治疗的肿瘤组织和治疗剂。

公开(公告)号：US11795218B2

公开(公告)日：2023-10-24

申请号：US16795468

申请日：2020-02-19

Applicant: BioNTech AG ,  Ganymed Pharmaceuticals GmbH ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Korden Walter ,  Meike Wagner ,  Maria Kreuzberg ,  Sabine Hacker ,  Stefan Jacobs

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K33/243 ,  C07K16/30 ,  A61K47/68 ,  G01N33/574 ,  A61N5/10 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K33/243 ,  A61K39/39558 ,  A61K47/6851 ,  A61N5/10 ,  C07K16/30 ,  G01N33/57484 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  G01N2333/705 ,  G01N2800/52

Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

公开(公告)号：US10724103B2

公开(公告)日：2020-07-28

申请号：US15675148

申请日：2017-08-11

Applicant: BioNTech AG

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sandra Schneider ,  Gerd Helftenbein ,  Volker Schluter ,  Dirk Usener ,  Philippe Thiel ,  Michael Koslowski

IPC: C12Q1/686 ,  C12Q1/6886 ,  C07K14/47 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  C07K16/30 ,  G01N33/53

Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.

公开(公告)号：US10428149B2

公开(公告)日：2019-10-01

申请号：US15558372

申请日：2016-03-18

Applicant: UNIVERSITÄT STUTTGART ,  BIONTECH AG

Inventor： Ugur Sahin ,  Roland Kontermann ,  Klaus Pfizenmaier ,  Martin Siegemund ,  Meike Hutt ,  Oliver Seifert

IPC: C07K16/32 ,  C07K16/28 ,  C07K14/705

Abstract: The present invention relates to a polypeptide comprising a component A with at least three tumor necrosis factor (TNF) homology domains of TNF-ligand family members (THD) in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof, and a component B comprising a dimerization domain. Further, the present invention relates to a polypeptide comprising at least three THDs in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof. Further, the invention relates to a nucleic acid comprising said polypeptides, a vector comprising said nucleic acid and a pharmaceutical composition comprising said polypeptides, or said nucleic acids or said vector. Further, the present invention relates to said polypeptides, said nucleic acid or said vector for the use as a medicament or for the use in the diagnosis, prophylaxis or treatment of hyperproliferative disorders and inflammatory disorders.

公开(公告)号：US10302647B2

公开(公告)日：2019-05-28

申请号：US14887979

申请日：2016-03-07

Applicant: BioNTech AG

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Michael Koslowski ,  Gerd Helftenbein ,  Dirk Usener ,  Volker Schluter

IPC: C12Q1/686 ,  G01N33/574 ,  C12Q1/6886 ,  G06F19/22

Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.